On October 17, 2025, RedHill Biopharma completed a strategic transaction with Cumberland Pharmaceuticals involving Talicia®, its proprietary drug, by selling a 30% equity stake in newly formed Talicia ...

RedHill Biopharma says it’s getting good results in clinical trials using ondansetron pills to help alleviate side effects such as nausea, vomiting and diarrhea among people using the blockbuster ...

Revenue-generating with an exciting, diversified, largely externally funded, advanced development pipeline and multiple upcoming catalysts. Recent highlights: Mr. Ben-Asher continued: "Having ...

RedHill Biopharma (RDHL) announced positive results from new in vivo studies of opaganib as a treatment for gastrointestinal acute radiation syndrome, or GI-ARS, undertaken as part of the U.S.

RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing ...

Haynes Boone represented RedHill Biopharma Ltd. in an appellate case, where the court affirmed a $6.5 million summary judgment in addition to interest and costs for RedHill. Simplicity won the day in ...

RedHill Biopharma Ltd. (NASDAQ:RDHL) shares climbed 16.5% in premarket trading on Monday after the company reported advances ...

Strong Use of Composition-of-Matter Coverage: Patent protects the molecular structure of RHB-107, providing market exclusivity beyond method-of-use claims COVID-19 Therapeutic Use: Includes coverage ...

Under the terms of the agreement RedHill will receive $500,000 in guaranteed payments, including a $250,000 upfront payment and $250,000 in fixed payments due within 18 months, plus a minimum of $1.3 ...

RedHill Biopharma (RDHL) announced the new publication of positive in vivo data, in the journal Diabetes, Metabolic Syndrome and Obesity, in an article entitled “Opaganib Promotes Weight Loss and ...

The accompanying notes are an integral part of these condensed consolidated financial statements. [1] Including cash, cash equivalents, short-term bank deposits and restricted cash. [2] All financial ...

According to RedHill, while over 2% of Americans take GLP-1 receptor agonists, estimates suggest up to 50% discontinue treatment within three months due to side effects. Goldman Sachs estimates this ...